Potencjalne możliwości wykorzystania berberyny w przeciwdziałaniu insulinooporności i w cukrzycy typu 2
References
- Rad S.Z., Rameshrad M., Hosseinzadeh H.: Toxicology effects of Berberis vulgaris (barberry) and its active constituent, berberine: A review. Iran J. Basic. Med. Sci., 2017; 20: 516-529
- Wojciechowska I.: Berberys pospolity – roślina ozdobna i lecznicza. Kosmos. Problemy Nauk Biol., 2017; 66: 487-490
- Yu Y., Liu L., Wang X., Liu X., Liu X., Xie L., Wang G.: Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem. Pharmacol., 2010; 79: 1000-1006
- Zhang H., Wei J., Xue R., Wu J.D., Zhao W., Wang Z.Z., Wang S.K., Zhou Z.X., Song D.Q., Wang Y.M. i wsp.: Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism, 2010; 59: 285-292
- Xing L.J., Zhang L., Liu T., Hua Y.Q., Zheng P.Y., Ji G.: Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in non-alcoholic fatty liver disease (NAFLD) rat liver. Eur. J. Pharmacol., 2011; 668: 467-471
- Xia X., Yan J., Shen Y., Tang K., Yin J., Zhang Y., Yang D., Liang H., Ye J., Weng J.: Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One, 2011; 6: e16556
- Abd El-Wahab A.E., Ghareeb D.A., Sarhan E.E., Abu-Serie M.M., El Demellawy M.A.: In vitro biological assessment of Berberis vulgaris and its active constituent, berberine: Antioxidants, antiacetylcholinesterase, anti-diabetic and anticancer effects. BMC Complement. Altern. Med., 2013; 13: 218
- Boudjelthia K., Hammadi K., Kouidri M., Djebli N.: Evaluation of antidiabetic activity of two plants Berberis vulgaris and Zygophyllum geslini. J. Phys. Chem. Biophys., 2017; 7: 236
- Chakrabarti R., Bhavtaran S., Narendra P., Varghese N., Vanchhawng L., Shihabudeen M.S., Thirumurgan K.: Dipeptidyl peptidase-IV inhibitory activity of Berberisaristata. J. Nat. Prod., 2011; 4: 158-163
- Jiang S.J., Dong H., Li J.B., Xu L.J., Zou X., Wang K.F., Lu F.E., Yi P.: Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats. World J. Gastroenterol., 2015; 21: 7777-7785
- Furrianca M.C., Alvear M., Zambrano T., Fajardo V., Salazar L.A.: Hypoglycemic effect of Berberis microphylla G Forst root extract. Trop. J. Pharm. Res., 2017; 16: 2179-2184
- Xu M., Xiao Y., Yin J., Hou W., Yu X., Shen L., Liu F., Wei L., Jia W.: Berberine promotes glucose consumption independently of AMP-activated protein kinase activation. PLoS One, 2014; 9: e103702
- Zhang H., Wang X., Wang T., Chen K., Wang H., Jia Q., Li Y.: Enhancement of berberine hypoglycemic activity by oligomeric proanthocyanidins. Molecules, 2018; 23: 3318
- Liu D., Zhang Y., Liu Y., Hou L., Li S., Tian H., Zhao T.: Berberine modulates gut microbiota and reduces insulin resistance via the TLR4 signaling pathway. Exp. Clin. Endocrinol. Diabetes, 2018; 126: 513-520
- Zhong Y., Jin J., Liu P., Song Y., Zhang H., Sheng L., Zhou H., Jiang B.: Berberine attenuates hyperglycemia by inhibiting the hepatic glucagon pathway in diabetic mice. Oxid. Med. Cell. Longev., 2020; 2020: 6210526
- Liu L., Yu Y.L., Yang J.S, Li Y., Liu Y.W., Liang Y., Liu X.D., Xie L., Wang G.J.: Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn. Schmiedebergs. Arch. Pharmacol., 2010; 381: 371-381
- Gong J., Hu M., Huang Z., Fang K., Wang D., Chen Q., Li J., Yang D., Zou X., Xu L. i wsp.: Berberine attenuates intestinal mucosal barrier dysfunction in type 2 diabetic rats. Front Pharmacol., 2017; 8: 42
- Zhang Q., Xiao X., Feng K., Wang T., Li W., Yuan T., Sun X., Sun Q., Xiang H., Wang H.: Berberine moderates glucose and lipid metabolism through multipathway mechanism. Evid. Based Complement. Alternat. Med., 2011; 2011: 924851
- Gomes A.P., Duarte F.V., Nunes P., Hubbard B.P., Teodoro J.S., Varela A.T., Jones J.G., Sinclair D.A., Palmeira C.M., Rolo A.P.: Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. Biochem. Biophys. Acta, 2012; 1822: 185-195
- Mi J., He W., Lv J., Zhuang K., Huang H., Quan S.: Effect of berberine on the HPA-axis pathway and skeletal muscle GLUT4 in type 2 diabetes mellitus rats. Diabetes Metab. Syndr. Obes., 2019; 12: 1717-1725
- Chen C., Zhang Y., Huang C.: Berberine inhibits PTP1B activity and mimics insulin action. Biochem. Biophys. Res. Commun., 2010; 397: 543-547
- Yang J., Yin J., Gao H., Xu L., Wang Y., Xu L., Li M.: Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evid. Based Complement. Alternat. Med., 2012; 2012: 363845
- Chang W., Zhang M., Li J., Meng Z., Wei S., Du H., Chen L., Hatch G.M.: Berberine improves insulin resistance in cardiomyocytes via activation of 5′-adenosine monophosphate-activated protein kinase. Metabolism, 2013; 62: 1159-1167
- Zhang B., Pan Y., Xu L., Tang D., Dorfman R.G., Zhou Q., Yin Y., Li Y., Zhou L., Zhao S. i wsp.: Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3. Endocrine, 2018; 62: 576-587
- Chen Y., Wang Y., Zhang J., Sun C., Lopez A.: Berberine improves glucose homeostasis in streptozotocin-induced diabetic rats in association with multiple factors of insulin resistance. ISRN Endocrinol. 2011; 2011: 519371
- Xue M., Yang M.X., Zhang W., Li X.M., Gao D.H., Ou Z.M., Li Z.P., Liu S.H., Li X.J., Yang S.Y.: Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. Int. J. Nanomedicine, 2013; 8: 4677-4687
- Almani S.A., Memon I.A., Shaikh T.Z., Khoharo H.K., Ujjan I.: Berberine protects against metformin-associated lactic acidosis in induced diabetes mellitus. Iran J. Basic Med. Sci., 2017; 20: 511-515
- Pérez-Rubio K.G., González-Ortiz M., Martínez-Abundis E., Robles-Cervantes J.A., Espiinel-Bermúdez M.C.: Effect of berberine administration on metabolic sydrome, insulin sensitivity, and insulin secretion. Metab. Syndr. Relat. Disord., 2013; 11: 366-369
- Chen L, Lu W, Li Y. Berberine ameliorates type 2 diabetes via modulation of Bifidobacterium species, tumor necrosis factor-α, and lipopolysaccharide. Int. J. Clin. Exp. Med., 2016; 9: 9365-9372
- Memon M.A., Khan R.N., Riaz S., Ain Q.U., Ahmed M., Kumar N.: Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients. J. Res. Med. Sci., 2018; 23: 110
- Sheng Z.X., Xie D.H.: Therapeutic effect of berberine on the levels of inflammatory factors in type 2 diabetic patients. New Med., 2010; 4: 177-180
- Cao C., Su M.: Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. Exp. Ther. Med., 2019; 17: 3009-3014
- Shidfar F., Ebrahimi S.S., Hosseini S., Heydari I., Shidfar S., Hajhassani G.: The effects of Berberis vulgaris fruit extract on serum lipoproteins, apoB, apoA-I, homocysteine, glycemic control and total antioxidant capacity in type 2 diabetic patients. Iran J. Pharm. Res., 2012; 11: 643-652
- Di Pierro F., Villanova N., Agostini F., Marzocchi R., Soverini V., Marchesini G.: Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab. Syndr. Obes., 2012; 5: 213-217
- Derosa G., Bonaventura A., Bianchi L., Romano D., D’Angelo A., Fogari E., Maffioli P.: Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. J. Biol. Regul. Homeost. Agents, 2013; 27: 717-728
- Di Pierro F., Bellone I., Rapacioli G., Putignano P.: Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diabetes Metab. Syndr. Obes, 2015; 8: 89-96
- Guarino G., Strollo F., Carbone L., Della Corte T., Letizia M., Marino G., Gentile S.: Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Silybum marianum: A 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes. J. Biol. Regul. Homeost. Agents, 2017; 31: 495-502
- Li M.F., Zhou X.M., Li X.L.: The effect of berberine on polycystic ovary syndrome patients with insulin resistance (PCOS-IR): A meta-analysis and systematic review. Evid. Based Complement Alternat. Med., 2018; 2018: 2532935
DOI: https://doi.org/10.2478/ahem-2021-0038 | Journal eISSN: 1732-2693
Language: English
Page range: 790 - 801
Submitted on: Oct 30, 2020
Accepted on: Jul 14, 2021
Published on: Nov 29, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Related subjects:
© 2021 Michalina Mróz, Katarzyna Pastusiak, Paweł Bogdański, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.